Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 14/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.53 |
| ▸ | CLK2 | P49760 | 10/20 | 0.52 |
| ▸ | CLK3 | P49761 | 10/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14792731 | 0.88 | DYRK1A (0.58) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL14792142 | 0.88 | WNT1 (0.60) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL14792936 | 0.87 | DYRK1A (0.63) | WNT1DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL14792571 | 0.86 | WNT1 (0.62) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL14792110 | 0.85 | WNT1 (0.61) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL14785617 | 0.84 | DYRK1A (0.63) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL17364513 | 0.84 | DYRK1A (0.54) | WNT1DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL17096231 | 0.84 | WNT1 (0.80) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL14792165 | 0.84 | WNT1 (0.80) | WNT1DYRK1ACLK2CLK3 | |
| SCHEMBL14792167 | 0.83 | WNT1 (0.79) | WNT1DYRK1ACLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2013-03-28 | — | — | US | disclosed |
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079329-A1 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS | WNT3, WNT1, WNT3A | WNT1 2/4885DYRK1A 733/4885CLK2 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.